Exhibition Review | Chirial CPHI China 2024 concluded successfully!
★ Exhibition Review ★
The 3-day 22nd China Pharmaceutical Raw Materials Exhibition (CPHI China 2024) came to a successful conclusion on June 21, 2024 at the Shanghai New International Expo Center.
▶ Exhibition site
Geum Ran Biotech once again participated in this globally acclaimed industry event. The Geum Ran Biotech booth was bustling with visitors from both China and abroad, showing great interest in the chiral compound synthesis technology on display. Geum Ran Biotech utilizes its leading and unique synthetic biology technology to not only improve product quality and purity, but also significantly reduce production costs and environmental impact, contributing to global green and sustainable development. Furthermore, Geum Ran Biotech's rigorous and comprehensive quality control system ensures product quality and safety, earning the trust and praise of its customers.
▶ Communication and negotiation
During the exhibition, Jinran Biotech also held in-depth discussions and discussions with numerous clients in the pharmaceutical, health care, and cosmetics sectors, establishing extensive partnerships. These clients highly praised Jinran Biotech's technical strength and product quality, and expressed their willingness to further strengthen their collaboration with Jinran Biotech to jointly promote the development of related industries.
▶ Looking to the future
In short, Jinran Bio's impressive appearance at the exhibition not only showcased its leading and unique technology, but also conveyed its unwavering commitment to green, environmentally friendly, and sustainable development. We have reason to believe that Jinran Bio will continue to make greater contributions to innovation and development in the field of synthetic biological technology in the future.
▶ Introduction to Chirial
Founded in June 2020, the company currently operates two major production and R&D bases in Xuzhou and Nanjing, and has established in-depth scientific research collaboration and project partnerships with more than 5 universities. Leveraging the founding team's over 10 years of industrialization experience in synthetic biology, the company focuses on the design, R&D, production and sales of a range of novel biodegradable chiral advanced materials. At present, it boasts several platform technologies, including big data analysis and directed evolution of enzymes, screening and scale-up of green catalytic chiral compounds, as well as biodegradable material polymerization and performance testing platforms. The company's current product portfolio covers multiple pipelines, including high-end cosmetic actives, new-type health food additives, chiral pharmaceutical intermediates and biodegradable eco-friendly materials.
